Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Merck KGaA Add to portfolio

DAXX:MRK, Sep 21, 03:29 UTC

Latest DAXX:MRK News

Filter your feed

Apply Filter

Wednesday, June 12


News

Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer

MRK

With the latest approval, Keytruda can be prescribed to previously untreated patients with metastatic or with unresectable, recurrent HNSCC as monotherapy in patients whose tumors express PD-L1 [CPS (combined proportion score )≥1) or in combination with chemotherapy regardless of PD-L1 expression. The sBLA was based on data from the phase III KEYNOTE-048 study, wherein Keytruda, as a monotherapy and in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, demonstrated significant improvement in overall survival compared to the standard of care in the given patient population. Keytruda generated sales of $2.27 billion in the first quarter of 2019, up around 5.6% sequentially and 55% year over year. In fact, the Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in more than 1000 studies, including more than 600 combination studies.

Read Full Details

Topics:
  • Business
  • Health
  • Entertainment

Tuesday, June 11


News

Merck's Keytruda wins FDA approval to treat head and neck cancer

MRK

Merck's Keytruda wins FDA approval to treat head and neck cancer. ReutersJune 11, 2019, 10:56 AM UTC. June 11 (Reuters) - Merck & Co Inc said on Tuesday its blockbuster cancer drug Keytruda won approval from the U.S. Food and Drug Administration to treat a type of head and neck cancer. The drug was approved for use as a monotherapy, as well as in combination with a common chemotherapy regimen, to treat previously untreated patients with head and neck squamous cell carcinoma, Merck said. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Shailesh Kuber). What to read next.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Monday, June 10


News

Merck announces appointments in digital technology operating unit

MRK

Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, recently announced new leadership of Antelliq and its well-recognized and market-leading brands of Allflex Livestock Intelligence, Sure Petcare and Biomark. Rick DeLuca, President, Merck Animal Health, made these appointments following the completion of its acquisition of Antelliq, which is an operating unit within Merck Animal Health. “I am delighted and honored to announce these significant appointments as we begin an exciting new stage of our business journey, which will extend the range of market-leading technology and services for our customers,” said Rick DeLuca. Most recently, Bolton was Group Chief Operating Officer of Antelliq and served as President of Allflex North America from 2004 through 2014.

Read Full Details

Topics:
  • Business
  • Financial
  • Science
News

Merck Strikes $773M Deal For Privately Held Tilos Therapeutics

MRK

Keeping in line with the biotech M&A frenzy seen for much of the year, Merck & Co., Inc. (NYSE: MRK) announced a deal Monday to buy Tilos Therapeutics. Only recently, the pharma giant agreed to buy Peloton Therapeutics in a deal valued at up to $2.2 billion. Merck struck an agreement to buy privately held Tilos, which develops therapies targeting the latent transforming growth factor — or TGT-beta — complex for treating cancer, fibrosis and autoimmune diseases, for up to $773 million, including an upfront payment as well as contingent milestone payments. "Tilos has developed a compelling portfolio of candidates that employ a novel approach to modulating the potent signaling molecule TGF-beta by binding to latency-associated peptide, with potential applications across a range of disease indications," Dean Li, senior vice president for discovery and translational medicine at Merck Research Laboratories, said in a statement.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial
News

The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca

MRK AZN +5 more MRK AZN AZN LLY DTRUMP CVX CSCO

This week was ruled by cancer data presentations at the annual meeting of the American Society of Clinical Oncology (“ASCO”) in Chicago by pharma bigwigs like Bristol Myers, Merck and Roche among others. Follow up lung cancer data from the KEYNOTE-189 study showed that Keytruda in combination with Lilly’s Alimta (pemetrexed) and platinum chemotherapy reduced the risk of death by 44% compared with chemotherapy alone as a first-line treatment option for metastatic non-squamous non-small cell lung cancer (NSCLC) in patients with no EGFR or ALK genomic tumor aberrations. Merck and partner AstraZeneca announced detailed data from the phase III POLO study evaluating Lynparza for germline BRCA-mutated metastatic pancreatic cancer patients who did not progress on chemotherapy. The data showed that at six months, more than twice as many patients being treated with Lynparza were progression free compared to those on placebo.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Merck to buy Tilos Therapeutics in deal valued at up to $773 million

MRK

Merck & Co. Inc, in its second megadeal involving a cancer therapy developer in as many months, entered into a definitive agreement Monday to acquire Tilos Therapeutics in a transaction valued up to $773 million. Tilos, based in Lexington, Mass., is a biopharmaceutical company that has developed a portfolio of new drug candidates that employ a novel approach to modulating the potent signaling molecule known as TGFβ. Tilos is developing treatments not only for cancer, but also for fibrosis and autoimmune disorders.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Technology
News

Merck to Acquire Tilos Therapeutics

MRK

Under the terms of the agreement, Merck, through a subsidiary, will acquire all outstanding shares of Tilos for total potential consideration of up to $773 million, including an upfront payment as well as contingent milestone payments. “We are proud that the Tilos team has advanced the discoveries of our scientific founders by developing a portfolio of anti-LAP antibodies designed to realize the full potential of TGFβ-modulating therapeutics,” said Dr. Barbara Fox, CEO, Tilos. TGFβ is a potent cytokine believed to play an important role in the development of cancer and fibrotic diseases. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Science
  • Technology

Thursday, June 06


News

Better Buy: GlaxoSmithKline vs. Merck

MRK GSK +1 more MRK GSK GSK

Merck is by far the bigger one, though, with a market cap roughly twice that of GlaxoSmithKline (GSK). However, less than a decade ago GSK was the bigger company. Merck's stock performance has handily beaten GSK's in recent years. But which of these two drugmakers is better positioned to deliver solid returns to investors? GSK CFO Iain MacKay reaffirmed the drugmaker's projected dividend for 2019 in its Q1 conference call in May. What about growth prospects? New HIV drug Juluca is performing very well after receiving regulatory approvals last year. However, growth has slowed considerably for its two other dolutegravir-based HIV drugs, Tivicay and Triumeq.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Wednesday, June 05


News

Global Immunotherapy Drugs Market to 2025: Market will Grow at a CAGR of 12.5% - Key Vendors are AbbVie, Amgen, F. Hoffmann-La Roche, Bristol-Myers Squibb, Johnson & Johnson, & Merck & Co

MRK AMGN +2 more MRK AMGN JNJ ABBV

DUBLIN, June 5, 2019 /PRNewswire/ -- The "Global Immunotherapy Drugs Market - Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025" report has been added to ResearchAndMarkets.com's offering. The introduction of a novel product with affordable drug cost is expected to increase the competition among the market players.Many companies are currently focused on approvals, collaboration, and development of new products related to immunotherapy drugs due to increased demand for this therapy to treat various disease types.For instance, in January 2019, BioNTech AG inked a deal with MAB Discovery GmbH to acquire MAB's operational antibody generation unit. The acquisition helps to expand BioNTech, which is a top privately-held developer of RNA-based therapeutics, further into monoclonal antibody (mAb) development to develop new treatments that combine technologies of both the companies. In June 2018, Novartis received European approval for Aimovig, for the prevention of migraine in adults, and it works by blocking the activity of calcitonin gene-related peptide (CGRP) that is involved in migraine attacks.

Read Full Details

Topics:
  • Business
  • Health

Tuesday, June 04


News

IMV Inc. to Provide Update on Phase 2 Clinical Results with Merck Keytruda in DLBCL by Means of Conference Call and Webcast on June 12, 2019

MRK

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company, announced today that it will hold a conference call and webcast on Wednesday, June 12, 2019, at 8:00 a.m. Financial analysts are invited to join the conference call by dialing (866) 211-2304 (U.S. and Canada) or (647) 689-6600 (International) using the conference ID: 9685423. Other interested parties will be able to access the live audio webcast at this link: https://ir.imv-inc.com/events-and-presentations. IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Science